AMGEN Inc
NASDAQ: AMGN
$316.57
+$2.86 (+0.9%)
Real Time Data Delayed 15 Min.
AMGN Articles
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
Published:
A biosimilar application filing from Apotex has been accepted by the Food and Drug Administration for version of Amgen's Neulasta.
Published:
The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Published:
ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or...
Published:
Last Updated:
ThinkstockAmgen Inc. (NASDAQ: AMGN) announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer. This includes phase 3 RILOMET-1 and RILOMET-2 studies....
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.
Published:
A new research note from Cowen focuses on health care companies that have released earnings and offer investors reasons to own the stocks.
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Wednesday, October 29, 2014.
Published:
Amgen reported better-than-expected third-quarter 2014 results after markets closed Monday afternoon.
Published:
Last Updated:
Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.
Published:
Jon OggAmgen Inc. (NASDAQ: AMGN) used to be the king of biotech by size. That was then, and now is the time for a break-up or other efforts. At least that is the case brought by Third Point LLC and...
Published:
Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
Published:
The short interest data are out for the end of September settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Published:
A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could be of the blockbuster variety.
Published:
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most recent report.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.